Pharmacy Grand Rounds
DOACs in Chronic Kidney Disease and End-Stage Renal Disease: Is it DOAble?

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST) 

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

The use of direct-acting oral anticoagulants for the management of non-valvular atrial fibrillation and venous thromboembolism has increased since their introduction to the market. The presence of co-existing renal dysfunction complicates the safety and efficacy of these treatment options. This presentation will review the new evidence regarding safety and efficacy of apixaban and rivaroxaban in patients with chronic kidney disease and end-stage renal disease.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Review pharmacokinetic changes relevant for apixaban and rivaroxaban in chronic kidney disease and end stage renal disease.
• Discuss current recommendations for use and dosing of apixaban and rivaroxaban in patients with renal dysfunction.
• Summarize new evidence for the safety and efficacy of three pharmacologic oral anticoagulation options for atrial fibrillation and venous thromboembolism in patients with chronic kidney disease and end-stage renal diseases

Session Announcement

Session Slides

FACULTY INFORMATION

Stephanie Bellrichard, PharmD
PGY1 Pharmacy Resident
Mayo Clinic Health System - La Crosse, MN

Stephanie received a Doctor of Pharmacy degree from Creighton University in Omaha, NE.  She is a current PGY1 Pharmacy Resident at Mayo Clinic Health System – La Crosse with clinical practice interests in family medicine and surgery. 

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Stephanie Bellrichard, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation.

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Jennifer Elmer, DNP, APRN, CCNS, FCCM
• Mary Ellen Cordes, APRN, CNS, MS
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS